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1.INTRODUCTION 
Organophosphorus compounds have assumed considerable importance in 
most parts of the world particularly developing countries but also in western 
countries.
1 
Hospital based statistics suggest that nearly half of the admissions in 
emergency with acute poisoning are due to Organophosphorous compound 
poisoning.
2
The toxicity of those compounds and paucity of appropriate medical 
facilities lead on to a high fatality rate. These compounds first discovered more 
than 100 years ago are at present the predominant group of insecticides employed 
globally for pest control.
3 
Organophosphorous compound poisonings are found to 
be a leading cause of death in agricultural countries globally.
4-5 
 
Their easy accessibility along with socio-cultural factors play a considerable role in 
the selection of Organophosphates as a main suicidal poison and is most often 
preferred by young economically productive age group with a case fatality ratio 
around 20 percent. WHO estimates about 3 million people are being exposed to 
pesticide poisoning every year with about 2,00,000 deaths per year in developing 
countries.
6 
. India has the highest incidence of OP poisoning in the world. Nearly 
90% of the poisoning are suicidal with a fatality rate of >10% ; 8-10% accidental 
2 
 
and <1% Homicidal. Occupational exposure accounts for 1/5
th 
of accidental 
poisoning with fatalities of <1%. 
7
 
The organophosphorous compounds are the organic derivatives of 
phosphorous containing acids. The phosphonate, which are organic derivatives of 
phosphoric acid are, not used as insecticides but are used as chemical warfare 
agents. Organophosphorous compounds combine with esteratic sites of acetyl 
cholinesterase, that is phosphorylated & phosphorylated esteratic sites undergo 
hydrolysis. The phosphorylated enzyme is inactive and thus unable to hydrolyze 
acetylcholine. The biological effects of organophosphorous compound are as a 
result of accumulation of endogenous acetylcholine at sites of cholinergic 
transmission. This causes disruption of transmission of nerve impulses in both 
peripheral and central nervous system. Most organophosphorous compounds are 
readily absorbed through respiratory, oral and gastrointestinal mucous membrane, 
and through intact skin, as they are lipid soluble. This binding is irreversible, 
except with early pharmacological intervention.
8
 
The diagnosis is based on the history of exposure and features of cholinergic 
overactivity.
9 
The treatment includes atropine or glycopyrrolate, which acts as a 
physiological antidote and oximes which help in reactivating the enzyme. 
3 
 
Complications like respiratory failure, CNS depression and ventricular arrhythmias 
should be anticipated and treated.  
Cardiac manifestations often accompany poisoning with these compounds 
including, hypotension, hypertension, sinus bradycardia, sinus tachycardia & 
cardiac arrest. Electrocardiographic changes reported in previous studies include 
Sinus tachycardia, Sinus bradycardia, QTc prolongation, ST-T changes, along with 
various forms of arrhythmias, which may be serious and fatal. These complications 
are potentially preventable, if recognized early and treated adequately. 
Organophosphate poisoning has been postulated both in animal and human studies 
to cause myocardiotoxic damage (myocardial necrosis). Electrocardiographic 
changes in organophosphate compound poisoning have been reported along with 
the associated structural myocardial damage. Organophosphate compound 
poisoning itself causes diarrhoea and vomiting which can lead to electrolyte 
derangements which by themselves may impart electrocardiographic changes. 
Thus, this study is undertaken to study the electrocardiographic changes of 
organophosphate poisoning, which is so far much less studied and evaluate the 
importance of these changes in organophosphate compound poisoning considering 
the mortality and sufferings of those patients.  
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2.REVIEW OF LITERATURE 
HISTORICAL REVIEW  
Organophosphorous compounds and carbomates that were first discovered 
more than 100 years ago, are at present the predominant groups of insecticides 
employed globally for pest control. The compounds are toxic to humans and 
represent an important source of poisoning domestically, in some occupation or 
when ingested as a suicidal agent.
5 
 
During the past four decades, more than 35,000 different formulations have 
come into use as pesticides.
14 
Of these, organophosphorous insecticides are 
possibly the most widely used in the world. The majority of the Patients (79% in a 
study) were less than 30 years of age.
15 
 
Modern investigations of organophosphorous compound date from 1932 
when Lange and Krugger recorded the synthesis of dimethyl & diethyl 
phosphofluoridates. They noted that these compounds caused a persistent choking 
sensation and blurring of vision. This observation led Schrader of I.G. Farben 
industries to develop organophosphorous compound, first as agricultural 
insecticides and later as potential chemical warfare agents. Consequently, during 
World War II, several toxic compounds were developed and used as nitrogen gases 
5 
 
in Germany. 
16
In 1991, these very compounds formed the cornerstone of Iraq’s 
much-dreaded chemical warfare arsenal during the Gulf war. Organophosphorous 
compound first came to India in 1951, to be used as insecticides and in 1962 first 
Organophosphorous poisoning was reported in India.
17 
 
CHEMISTRY  
Organophosphorous compounds are usually esters /amides of thiol 
derivatives of phosphoric / phosphonic acids.  
The General formula being:  
R1                   O (or S)  
                         P ------------------------------X  
R2  
Where,  
R1 and R2 are usually simple alkyl or aryl groups.  
             X is known as the “leaving group” may be one of a wide variety of 
substituted or branched aliphatic, aromatic or heterocyclic groups linked to 
phosphorous via a bond of some liability usually –O-or -S-.  
             The double bonded atom may be O or S and the related compound, termed 
a phosphate or phosphorothioate
. 7  
6 
 
CLASSIFICATION  
Holmstedt proposed a classification system for organophosphorous that is of 
pharmacological and toxicological interest.  
The compounds are divided into 5 groups with a few relevant examples. 
16
 
Group A: (X: Halogen, Cyanide, and Thiocyanate)  
                    E.g.: Disopropylophosphate fluoridate (DFP)  
                             Isopropyl methyl phosphofluoridate (SARIN)  
                             Pinacolyl Methyl phosphofluoridate (SOMAN)  
Group B: (X: Alkyl, alkoxy, aryloxy)  
                    E.g.: Forstenon, DDVP, Pyrazoxon  
Group C: (X: Thiol or Thiophosphorous Compound)  
                    E.g.: Parathion, Malathion, Azethion, Diazinon, Systox, and Demeton  
Group D: (Pyrophosphates and related compounds)  
                    E.g.; TEPP, DPDA, OMPA  
Group E: (Quaternary Ammonium Compound)  
                    E.g.: Phospholin  
An older more commonly used classification divides these compounds into:  
1) Alkyl phosphates (Eg. TEPP, HETP, OMPA, Malathion, Systox, DFP etc).  
2) Aryl Phosphates (Eg. Demeton, Parathion, EPN, Chlorothion, Diazinon, etc).  
7 
 
PHARMACODYNAMICS & METABOLISM:  
These compounds are generally dispersed as aerosols /dusts, consisting of 
organophosphorous compound absorbed to an inert finely particulate material. 
Therefore practically all routes including gastrointestinal tract, skin and mucous 
membranes following contact with the liquid form, rapidly and effectively absorb 
these compounds. The lungs also absorb them, after inhalation of the vapors or 
finely dispersed dusts/ aerosols.  
Following absorption they quickly distribute in all tissues, maximum 
concentration usually being reached in the liver and the kidneys. Lipophilic 
compounds may reach high concentration in neural and other lipid rich tissues.  
Plasma half-life ranges from few minutes to few hours, depending on the 
compounds and route of administration.  
Metabolism occurs primarily by oxidation. Parathion is converted to 
biologically active compound – “Paroxon” by microsomal activation in the liver.  
Malathion is metabolized to inactive compound more rapidly in higher animals, 
and consequently is less dangerous to man.  
Highly lipid soluble agents such as Chlorfenthion may produce symptoms 
and signs of cholinergic over activity for an extended period of days to weeks, 
caused by subcutaneous lipid storage followed by subsequent chronic systemic 
8 
 
release after redistribution. These compounds also cause repeated release after 
apparently successful management.  
Detoxification of the organophosphorous insecticides occurs, either by bio-
chemical modification of their structure or by linkage to the binding site without 
toxicological significance.  
Elimination of organophosphorous compounds and their metabolites occur 
mainly through urine and faeces, with 80-90% of most of compounds being 
eliminated within 48 hours. A very small portion of organophosphorous 
compounds and their active forms are excreted unchanged in the urine.  
Some compounds are known to persist in the body for longer periods.  
MECHANISM OF ACTION  
Anticholinesterases bind to and inhibit a number of enzymes, yet it is their 
action on the esterase which is of clinical importance. 
7
 
a. Inhibition of Acetylcholinesterases (Ach E)  
Acetylcholinesterases (AchE) are responsible for the hydrolytic cleavage of 
Acetylcholine (Ach) to choline and acetic acid. Acetylcholine is a neurotransmitter 
for all postganglionic autonomic fibers, postganglionic parasympathetic fibers, 
postganglionic sympathetic fibers, neuromuscular junction and some interneuron 
synapses in the CNS. A potential reaction causes release of acetylcholine in the 
9 
 
presynaptic cleft, most of which is degraded by acetylcholinesterases. 
Acetylcholine, which is not degraded, binds to the postsynaptic receptors resulting 
in the generation of an excitatory postsynaptic potential and propagation of the 
impulse.  
Anti-acetylcholinesterase has two sites namely, anionic and esteratic site. 
Acetylcholine binds to the anionic site on acetylcholinesterases and undergoes 
hydrolysis in a few seconds. The reversible Anti-acetylcholinesterases combine 
with acetylcholinesterases at the anionic site and this blocks attachment of the 
substrate.
19
 
Irreversible Anti-acetylcholinesterases on the other hand binds to the 
esteratic site of the Acetylcholine and inhibit irreversibly thereby phosphorylating 
it. This leads to accumulation of acetylcholine at the synapses with initial 
overstimulation followed by inhibition of synaptic conduction.   
           Following inhibition, reactivation of the enzyme (acetylcholinesterase) 
occurs at the rate of 1% per day by slow de novo synthesis of fresh enzyme and 
also by spontaneous dephosphorylation.
20
 
The rate of inactivation (phosphorylation) and reactivation 
(dephosphorylation) depends of the species and the tissue in addition to the 
chemical group attached accounting for the differences in toxicity. 
21
 
10 
 
Response to reactivating agents decline with time, a process referred to as 
‘aging’ of the inhibited enzyme. It is a result of loss of an alkyl or alkoxyl group 
leaving a much more stable monoalkyl or monoalkoxyl phosphoryl 
acetylcholinesterase.
18
The aged phosphorylated enzyme cannot be reactivated by 
oximes.
22 
In chemical warfare agents like soman, aging occurs rapidly. 
20 
 
b. Inhibition of Neuropathy target esterase:  
Neuropathy target esterase (NTE)  inhibition followed by its transformation 
to an aged form is responsible for the organophosphate- induced delayed 
neuropathy (OPIDN).
23 
 
PATHOPHYSIOLOGY  
Acetylcholine is a neurotransmitter released by the terminal nerve endings of 
all postganglionic parasympathetic ganglia.  
There are three types of acetylcholinesterase enzyme present in the body; in 
red blood cells or true cholinesterase, serum pseudocholinesterase and brain 
cholinesterase.
24
 True cholinesterases are found primarily in nervous tissues and 
erythrocytes, while pseudo cholinesterases are present in plasma, liver and non-
neuronal tissues. Pseudo cholinesterase levels helps to diagnose a case of suspected 
poisoning.
7 
 
11 
 
The pathophysiological effects of organophosphates result from inhibition of 
ChE (both RBC and pseudo cholinesterase). These are the markers of exposure, 
acute toxic effects and reflect actual activity at cholinergic nerve terminal.
111 
  
In the acute phase of OP poisoning serum ChE activity is usually depressed 
within few hours to days and is also restored to normal levels quickly. About 3% 
of the population has a genetic variation manifested by a serum ChE deficiency. 
Pregnancy, acute (or) chronic inflammatory conditions,malnutrition and liver 
disease are conditions that also affect serum ChE levels, but the depression caused 
by these conditions are not as great as those caused by the organophosphate 
insecticides. This level can vary from person to person. A 50% reduction in 
ChE
50,75 
levels from the baseline may result in acute cholinergic symptoms of 
organophosphate exposure. These values differ among laboratories, and the range 
is very wide, with a 30% spread.
 112 
  
OP pesticides inhibit AchE at muscarinic and nicotinic synapses by 
depositing a phosphoryl group at the enzymes’ active site to form a temporary 
covalent bond which results in the accumulation of Ach and uncontrolled 
activation of cholinergic synapses. Over time, one of two processes will occur. The 
covalent bond may spontaneously cleave leaving the enzyme functional again. This 
process may take upto 1000 hours. Meanwhile the enzyme is prone to “Ageing” in 
12 
 
its active site in which one of the “R” group may cleave non-enzymatically, 
leaving a hydroxyl group in its place. Aged AChE with its negatively charged 
phosphate can no longer be attacked by a nucleophile, i.e. OH or an oximate group. 
And regeneration is no longer possible. Recovery of a functional pathway must 
wait until new ChE enzyme  is manufactured, a process that may take weeks. The 
time it takes for ageing to occur varies according to the specific pesticide, but takes 
no longer than 48 hours. Clinically the toxic effects of OP agents may persist more 
than a week.
 113 
Oximes slows down “ageing” of the phosphorylated cholinesterase 
and binds to the OP agent, making it non reactive. This results in ChE regeneration 
and a rise in serum levels of ChE.
 111 
  
  
 CLINICAL FEATURES  
The clinical manifestations of organophosphorous poisoning are a result of 
cholinergic over activity and can be divided into the effects of over stimulation of 
the muscarinic, nicotinic and CNS receptors.
5  
The clinical diagnosis is based on:  
 a. history of exposure  
 b. The presence of several of the symptoms and signs such as garlic odour, 
secretions, miosis, fasciculations, respiratory failure etc as to be discussed 
below.  
13 
 
 
      The time interval between the exposure and onset of symptoms and signs 
varies with the route and degree of exposure. The interval maybe within 5 minutes 
after massive ingestion and is almost always less than 12 hours. The severity of 
manifestation varies with the degree of poisoning.  
            In recent works, it has been reported that children, particularly less than 
nine years of age manifest “nicotinic” signs rather than “muscarinic” signs of 
poisoning. The most common features of paediatric poisoning are CNS depression 
and hypotonia.
113 
  
Namba et al
9 
have made a classification of organophosphorous poisoning 
insecticide which is modified from Grob et al
25 
and is as follows: -  
Latent poisoning: -  
No clinical manifestations are seen. Diagnosis based on estimation of serum 
cholinesterase activity, which is inhibited by 10 to 50%  
Mild poisoning: -  
The patient complains of fatigue, headache, dizziness, nausea, vomiting, excessive 
sweating, salivation, chest tightness, numbness of extremities, abdominal cramps 
or diarrhea. Serum cholinesterase levels are 20-50% of normal values.  
 
14 
 
Table 1:  Clinical features according to receptor stimulation 
 
Moderate poisoning: -  
The patient complains of generalized weakness, difficulty in talking, 
muscular fasciculations and miosis. Serum cholinesterase levels are 10-20% of 
normal values.  
 
15 
 
 
Severe poisoning: -  
Marked miosis, unconsciousness, loss of pupillary reflex to light, muscular 
fasciculation, flaccid paralysis, and secretions from the mouth and nose, rales in 
the lungs, respiratory difficulty and cyanosis are seen in patients with severe 
poisoning. Serum cholinesterase levels are lower than 10% of normal values.  
However, this proposed grading has proved unworkable in clinical practice 
because of many varied clinical criteria in different grades, as well as the difficulty 
in remembering and applying them in acute clinical situation.
5, 12
 
The second classification was proposed by Bardin et al
12 
and is as follows: -  
Grade 0 Nil                    Positive history  
                                      No signs of organophosphorous poisoning.  
Grade 1 Mild                 Mild secretions,  
                                      Few fasciculations,  
                                      Normal level of sensorium.  
Grade 2 Moderate         Copious secretions,  
                                     Generalized fasciculations,  
                                     Rhonchi, crepitations,  
                                     Hypotension (systolic BP <90mmHg)  
16 
 
                                     Disturbed level of consciousness, not stuperous  
Grade 3  Severe           Stupor,  
                                    PaO2 < 50mmHg,  
                                    Chest roentgenogram abnormal.  
This study by Bardin et al showed that patients with grade 3 manifestations 
on admission were associated with increased requirement for mechanical 
ventilator. The presence of other complications and increased days of ICU stay 
have been observed in the above patients.  
Grading of Fasciculation was done by giving 1 point depending on the 
presence of fasciculations each to the anterior chest, posterior chest, anterior 
abdomen, posterior abdomen, right thigh, left thigh, right leg, left leg, right arm 
and left arm. The total Fasciculation score is thus estimated.  
           Following organophosphorous poisoning three well-defined clinical phases
7 
are seen:  
 1. Initial acute cholinergic crisis.  
 2. The intermediate syndrome  
 3. Delayed Polyneuropathy (OPIDN-Organophosphorous Induced 
Delayed Neuropathy)  
17 
 
 In addition chronic organophosphate induced neuropsychiatric disorder 
(COPIND) can occur.  
1. Acute cholinergic phase:  
This is the initial phase of acute poisoning resulting in muscarinic and 
nicotinic effects. The accumulation of acetylcholine at the muscarinic site produces 
an increase in secretions. Bronchorrhea, salivation, sweating, bradycardia, 
vomiting and an increase in gastro-intestinal motility (abdominal tightness and 
cramps). In the eye, organophosphorous agents cause the diagnostic miosis which 
results in blurring of vision. The effects of increased acetylcholine at nicotinic 
sites. Eg: The neuromuscular junction, cause muscle fasciculation. Inhibition of 
acetylcholinesterase in the brain leads to headache, insomnia, giddiness, confusion 
and drowsiness. After severe exposure, slurred speech, convulsions, respiratory 
depression and coma occur.  
The mechanism of action for muscle paralysis is depolarization and 
desensitization blocks induced by acetylcholine at the neuromuscular junctions. 
Death is likely during this initial cholinergic phase due to effects on the heart like 
bradycardia, arrhythmias; respiratory failure and depression of vital centers in the 
brain. Cases with even vocal cord paralysis have been reported.
 49 
Bradycardia may 
be severe and may progress to heart block. The cholinergic phase usually lasts 24 
18 
 
to 48 hours and constitutes a medical emergency that required treatment in an 
ICU. 
20 
2. Intermediate syndrome  
Senanayake and Karallieda first coined the term “Intermediate syndrome” in 
1987.
28 
After recovery from the cholinergic crisis, but before the expected onset of 
delayed polyneuropathy, some patients develop a muscle paralysis, which is 
described as Intermediate syndrome. This phenomenon has been reported in 
between 20-68% of the patients.
29
 
           The development of IMS might be due to a conformational change in the 
acetylcholine receptor altering depolarizing neuromuscular block to a non-
depolarising block characterized by a fade on tetanic stimulation. 
The cardinal feature of this syndrome is muscle weakness affecting 
predominantly the proximal limb muscle and neck flexors. Motor cranial nerve 
palsies (III to VII and X) also occur. Respiratory muscle weakness leading to 
respiratory failure could lead to a fatal outcome. Deep tendon reflexes are usually 
depressed. The intermediate syndrome occurs after recovery from the cholinergic 
crisis within 24 hours to 96 hours but before the expected onset of the delayed 
neuropathy, which occurs 2 to 3 weeks after the poisoning.
4
 
19 
 
Complete recovery occurs within 4 to 18 days, if adequate ventilator support 
is provided. The agents commonly responsible are fenthion, monocrotophos, 
dimethoate, diazinon and methyl parathion.
30 
 
3. Delayed Polyneuropathy  
The neuropathy develops following latent periods of 2-4 weeks after the 
cholinergic crisis. The cardinal symptoms are distal muscle weakness, calf pain 
preceding the weakness and in some cases paraesthesia in the distal parts of the 
limbs. Weakness initially appears in the leg muscles causing foot drop, followed 
by small muscles of the hands. Later it may extend proximally and even involve 
the truncal muscles. Deep tendon jerks are absent. The prognosis of patients with 
mild neuropathy is good but those with severe neuropathy are usually left with 
persistent deficits that are claw hand, foot drop, persistent atrophy, spasticity and 
ataxias.  
Delayed Polyneuropathy is common following exposure to 
organophosphorous compounds, which have weak anticholinesterase activity Eg. 
Triorthocresylphosphate. The occurrence of Delayed Polyneuropathy appears to 
follow phosphorylation and subsequent aging of an enzyme in axons called as 
neuropathy target esterase (NTE). The function of this enzyme is not clear yet. It is 
however present in the brain, spinal cord and the peripheral nervous system. NTE 
is a membrane bound protein with high esterase catalytic activity. This 
20 
 
phosphorylation enzyme also undergoes ageing.
31 
The agents commonly 
responsible are mepafox and chloropyrifos.
32, 33, 34, 35
 
Chronic Organophosphate Induced Neuropsychiatric Disorder (COPIND)  
Behavioral effects have been documented following acute or chronic 
organophosphorous poisoning. These include,  
 a. Impairment of vigilance, information processing, psychomotor speed and 
memory.  
 b. Poor performance and perception of speech.  
 c. Increased tendency to depression, anxiety and irritability.  
 d. A tendency to faster frequencies and higher voltages in EEG.  
Extra pyramidal manifestations (dystonia, rest tremors, cogwheel rigidity and 
chorea-athetosis) 
35 
may occur four to forty days after organophosphorous 
poisoning. Recent studies suggest that Parkinson’s disease is a more common in 
patients who report to have had previous exposure to pesticides.
36
 
INVESTIGATIONS 
1. Arterial blood for oxygen and carbon dioxide partial pressures. 
2. Venous blood for estimation of red cell acetylcholinesterase and concentration 
of  the OP compound. 
21 
 
3 .Venous blood for estimation of biochemistry (electrolytes, glucose, amylase, 
lipase, creatinine) and haematology. 
4. Chest X-ray. 
5.Ultrasound scan of the abdomen (pancreatic status). 
DIAGNOSIS  
Diagnosis depends on the following factors:  
 a. History or evidence of exposure to anticholineserase agents.  
 b. Signs and symptoms of poisoning.  
 c. Improvement of these clinical features with atropine and PAM.  
 d. Inhibition of cholinesterase activity.  
    In most patients, a history of exposure to organophosphorous insecticide can 
be obtained. A container is usually found. History may be denied in attempts of 
suicide or unavailable in-patients who are found unconscious. Organophosphates 
impart a garlic-like odour to the breath, vomitus or faeces.
7
The signs of 
organophosphorous poisoning that are most helpful in diagnosis are miosis and 
muscle fasciculations. Others include excessive perspiration, salivation, 
Lacrimation and bronchial secretion.
7, 9
 
    The response to atropine therapy may also be useful aid to diagnosis, with 
patients who have organophosphorous poisoning showing a tolerance to atropine. 
22 
 
There is also failure to produce signs of atropinisation with 1 to 2mg of atropine 
administered intravenously.
5
 
   Inhibition of cholinesterase activity(50% reduction considered confirmatory) 
of the blood is also helpful. Estimation of erythrocyte cholinesterase (acetyl 
cholinesterase) is theoretically preferred as it reflects the degree of inhibition of 
synaptic cholinesterase. However, estimation of plasma cholinesterase (pseudo 
cholinesterase) can be done.
7, 5
 
  Estimation of blood sugar and urine acetone can help ruling out Diabetic 
ketoacidosis since it is an important differential diagnosis of OP poisoning, yet OP 
consumption itself may cause hyperglycemia. Serum amylase level is said to raise 
and has prognostic significance. X ray chest can clearly show pulmonary 
congestion and edema indicating the severity of poisoning. 
  Methods used for assay for AchE activity vary in sophistication. They include 
the classical electrometric method, the calorimetric method and a titrometric assay.  
TREATMENT  
All patients should be managed as emergencies in hospital.  
A. Acute Cholinergic Crisis: 
7 
 
Treatment is based on the following principles:  
23 
 
 a. Minimizing further absorption of the insecticide.  
 b. Pharmacologically countering the effects of the poison.  
 c. Maintaining vital functions.  
Successful management requires rapid and simultaneous implementation of 
the above principles.  
First aid measures should include removal of patient from the contaminated 
environment, removal of contaminated clothes and washing of the skin and eyes.  
Respiratory failure is the usual cause of death in the acute phase; 
resuscitation and artificial respiration may be required immediately. Mouth-to-
mouth respiration should not be attempted.  
Cardiac arrhythmias include various degrees of heart block and should be 
managed accordingly.  
Gastric lavage is most effective within 30 minutes of ingestion but is advised 
also at the time of admission after taking necessary precautions to protect the 
airway, adequate oxygenation and supportive invasive ventilation if needed. If the 
patient is semiconscious/unconscious, Ryle’s tube aspiration can be done. 
Activated charcoal, 1g/kg dose every 2-4 hours may be administered to reduce 
further absorption from the stomach except in cases of intestinal obstruction 
featured by absent bowel sounds, tense rigid abdomen.   
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Atropine:  
Treatment with anticholinergic medication is still the mainstay of treatment 
and should be started as soon as the airway has been secure. Full early 
atropinisation is an essential and simple part of an early management and a delay 
can result in death from central respiratory depression, bronchospasm, 
bronchorrhoea, severe bradycardia or hypotension. 
Atropine acts as a physiological antidote, effectively antagonizing the 
muscarinic-receptor-mediated action. It has virtually no effect against the 
peripheral neuromuscular dysfunction and subsequent paralysis induced by 
organophosphorous agent.  
A recommended dose is 2-4 mg intravenous, repeated at interval of 5-10 
minutes initially and continued until signs of atropinisation (dry axillae, clear 
lungs, no miosis, flushing of skin, systolic BP > 80 mm Hg and a heart rate of > 80 
beats/ minute) appear. Atropine therapy should be maintained until there is 
complete recovery. The maintenance dose is said to be about 10% of the dose 
needed for atropinisation as continuous infusion and needs to be adjusted 
according to the toxic features on observation. 
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Table 2: Atropine Recommendations 
SOURCE RECOMMENDED 
REGIMEN FOR 
ATROPINISATION 
MARKERS OF 
ATROPINISATION 
Harrison’s Internal medicine 18th 
Edition, 2011 
0.5mg repeated every 5-15 min Dry secretions 
Australian medicines hand book 
14th Edition, 2003  
2mg iv repeated until 
atropinisation is achieved then 
infusion titrated against clinical 
effects 
Abolish all secretions 
British national formulatory 
edition -46, 2003 
2mg repeated every 5-10 min. 
IM or IV according to severity 
Dry flushed skin, dilated pupils, 
tachycardia 
WHO model formulatory edition 
-1, 2002 
2 mg repeated every 20-30 min Flushed early skin and 
tachycardia 
 
Infusion of atropine are used in some centers in dose of 0.02-0.08 
mg/kg/hr.
51 
Infusion of atropine has produced significant reduction in mortality in 
some centers when compared to conventionally intermittent therapy.
52 
A heart rate 
exceeding 140 beats/minute should be avoided. ST-segment abnormalities in the 
ECG may be induced by large doses of atropine.
 74 
These may be corrected with 
propronalol, eliminating any need to reduce the rate of administration of atropine. 
Atropine crosses the blood brain barrier and may cause severe toxic effects such as 
convulsions, psychosis and coma,
53
 which if necessary should be corrected using 
Physostigmine 
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Glycopyrrolate:  
This is a quaternary ammonium compound that can be used as an alternative to 
atropine. The advantages of Glycopyrrolate over atropine are: -  
 a. Better control of secretions .
54 
 
 b. Less tachycardia.
55 
 
 c. Fewer CNS side effects.
56 
 
Oximes:  
The observation that oximes reactivates phosphorylated AchE more rapidly 
than spontaneous hydrolysis led to the development of Pralidoxime (Pyridine-2-
aldoxime methyl chloride, PAM) and later Obidoxime, Trimedoxime, Asoxime, 
HI6, HIo7 etc.  
The reactivating action of pralidoxime
78 
is most marked at the skeletal 
neuromuscular junction. It acts by reactivation of the inhibited phosphorylated 
enzyme to free the active form. Its dose is 500 mg/hour for severe poisoning and 
1gm 8-12 hourly for mild to moderate poisoning in adults and 25-50 mg/kg in 
children,  given intravenous in 250ml normal saline over 30 minutes. The WHO 
recommended Pralidoxime regimen is 30 mg/kg bolus followed by 8 mg/kg 
infusion.  It has no effect on the muscarinic effect. It has short half-life of 1.2 hours 
when given intravenous
57 
and does not cross the blood brain barrier.
16 
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PAM should be administered as early as possible,
26 
at least within 4-36 hours 
of poisoning for regeneration of AchE. It is dependent primarily on the life span of 
the erythrocytes when aging of the enzyme has occurred.
20 
 
PAM is available as chloride, iodide, mesylate and methyl sulfate salts. The 
chloride salt is more stable than iodide in dry state and is preferred for 
intramuscular use.  
The major pharmacological action of oximes is to reactivate AchE by 
removal of phosphate group bound to the esteritic site.
5 
This action occurs shortly 
after poisoning and inhibition of the enzymes, after which the enzyme ages and 
becomes more firmly bound to esteratic site.
58 
Oximes should be given as soon as 
possible before aging takes place. They are most effective if given within 6 hours 
of poisoning, but beneficial response is seen upto 24 hours of poisoning.  
The therapeutic effects of oximes seemed to depend on the plasma 
concentrations of the organophosphorous agent with the benefit being, minimal at 
high concentrations of organophosphorous in the blood. Pralidoxime does not cross 
the blood-brain barrier whereas obidoxime does.  
Paradoxically high doses of pralidoxime may cause neuromuscular block 
and other effects including inhibition of AchE.
16
High frequencies of cardiac 
28 
 
arrhythmias were observed in patients who received high cumulative doses of 
atropine and Obidoxime.  
Diazepam:  
Some reports have indicated that benzodiazepines are useful as antidotes in 
poisoning by anticholinesterases.
59 
This appears to counteract some aspects of CNS 
derived symptoms and also increase therapeutic effects of atropine and PAM.  
Diazepam is used to treat convulsions after organophosphorous poisoning 
and in the support of ventilatory care  
Fluoride:  
Fluoride and atropine combination produces a greater antidotal effect than 
atropine alone. 
20
 It was noted that increased cholinesterase levels were observed in 
workers in a plastic factory handling fluoride compounds.  
Magnesium:  
           Kiss and Fazekas
44 
reported that ventricular premature contractions were 
successfully eliminated with intravenous magnesium sulfate. The magnesium was 
thought to counteract direct toxic inhibitory effect of organophosphates on sodium-
potassium ATPase.  
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Phenothiazines:  
The use of phenothiazines in the management of organophosphorous 
poisoning is controversial. Diazepam has proved to be satisfactory and popular 
alternative.
7
 
Respiratory stimulants:  
Respiratory stimulants should not be used in the treatment of 
organophosphorous poisoning in humans, particularly, in view of the 
bronchospasm, neuromuscular block and convulsions that are associated with 
intoxication.
60 
 
Other measures:  
          Dialysis of  blood against activated charcoal (hemoperfusion) is effective in 
demeton-S-methyl sulphoxide, dimethoate and parathion poisoning.
61
Prompt 
improvements have been reported following repeated injections of purified 
lyophilised  human cholinesterase.
19 
Resealed cells containing a recombinant 
phosphotriesterase provided protection against the lethal effect of paraoxon. 
Phosphotriesterase hydrolyses paraoxon to the less toxic 4-nitrophenol and 
diethylphosphate. This enzyme was encapsulated into carrier erythrocytes by 
hypotonic dialysis with subsequent resealing and annealing. The encapsulated 
enzyme was found to persist longer and possess much greater efficacy. When these 
30 
 
carrier cells were administered in combination with pralidoxime chloride and 
atropine, a marked synergism was observed. The use of fresh plasma and exchange 
transfusions are of  little value. Corticosteroids, camphor, potassium chloride, 
clonidine and vitamin C have been used with varying degree of success. However, 
all these regimens need further evaluation.
7
  
Management of Intermediate Syndrome: 
7
 
Prompt and effective management of respiratory insufficiency is the 
cornerstone of treatment of Intermediate syndrome.  
Patients should be observed for early signs of respiratory failure and 
facilities for ventilatory care should be made available. Frequent blood-gas 
analyses are useful in monitoring and weaning from ventilatory support. Diazepam 
in 10 mg intravenous doses may be useful in anxious or restless patients on 
ventilator.  
Management of Delayed Neuropathy: 
7
 
No specific drug therapy has proved useful. The muscle weakness benefits 
from regular exercise and physiotherapy.  
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Complications  
Complications resulting from organophosphorous poisoning occur in about 
43% of cases with acute intoxication.
12, 62
 
Death can often occur early (within 24hours) in untreated cases and upto 10 
days in hospital with optimal management. 
63 
 
Early deaths are due to CNS depression, seizures, and ventricular 
arrhythmias (Eg. Torsade de pointes) or respiratory failure due to excessive 
bronchial secretions, pulmonary edema, aspiration pneumonia, respiratory muscle 
paralysis or respiratory center depression. 
10, 27
 
Late mortality is caused by respiratory failure
11, 12 
associated with infection 
(pneumonia, septicemia) or ventilator related complications.  
There are various studies in which respiratory failure was the commonest 
complication encountered following acute organophosphorous poisoning. 
64, 65
 
The pathogenesis is multifactorial and related to aspiration of gastric contents, 
excessive secretions in the airways, pulmonary infections, pneumonia, septicemia 
and development of ARDS. 
11
 
Respiratory consequences of muscarinic overstimulation including 
rhinorrhoea, bronchorrhea, bronchoconstriction and laryngeal spasm may 
32 
 
contribute to respiratory failure. These are often combined with nicotinic effects 
such as respiratory muscle weakness and paralysis (including paralysis of tongue 
and nasopharynx).  
Central depression of respiratory centre occurs following cholinergic 
overstimulation of synapses in the brain stem and is a prominent cause of hypoxia, 
respiratory failure and death in the early period of acute organophosphorous 
poisoning. 
10
 
Peripheral neuromuscular block producing respiratory muscle weakness and 
paralysis as well as the recently described intermediate neuropathy
28 
contributes to 
the development of respiratory insufficiency at a later stage.  
Sudden cardiovascular collapse is often the first indication of unsuspected 
or incipient respiratory failure, a presentation that is associated with a high 
mortality.
11
 
The development of pneumonia is the most important cause of delayed 
respiratory failure after organophosphorous poisoning and this occurs in upto 43% 
of the patients.
11, 13, 62 
Upto 80% of patients with pneumonia had respiratory failure; 
majority of these could be diagnosed within 96 hours of poisoning.
11
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          Inadequate or delayed atropinisation appears to be one of the principle 
reasons for the development of pneumonia
12 
and emphasis the importance of 
skilled medical assessment and treatment at an early stage after poisoning. 
Prevention: 
7
 
Preventive measures should be considered at all the levels of the chain of 
insecticide movement through the environment-formulation manufacture, mixing 
application and disposal.  
          Psychiatric counselling for prevention of second episode should always be 
given. General counseling and drug therapy for depression should be added. Strict 
guidelines should be adopted during transport and storage to prevent contamination 
of food, clothing, drugs, toys, cosmetics and furnishing.  
Other effects of organophosphorous intoxication  
Altered immunity to infection  
In 1974, Bellin and Chow 
37
suggested that organophosphorous agents might 
have an effect on the human immune system. Casali et al
38 
demonstrated that 
parathion suppressed both the primary IgM and IgG response to sheep erythrocytes 
in mice.  
34 
 
Newcombe
39 
showed an increased incidence of lymphoproliferative 
disorders associated with impaired natural killer cell and cytotoxic T-cell function.  
Murray et al
40 
reported influenza like symptoms in 23 patients after 
occupational exposure to organophosphorous compounds.  
Changes in metabolism and endocrine activity  
In animal experiments, changes in the diurnal pattern of plasma ACTH have 
been reported following organophosphorous poisoning. 
41
Nicotinic receptors also 
function in brain pathway that increases the release of several pituitary hormones 
including vasopressors, ACTH and prolactin. In man, nonketotic hyperglycemia 
may occur.
42, 43
 
Effects on Reproduction  
There is a report of termination of pregnancy following organophosphorous 
poisoning during the first trimester.
47 
In experimental animals, organophosphorous 
poisoning during pregnancy cause pre- and postnatal death and congenital 
abnormalities such as vertebral deformities, limb defect, polydactyl and cleft 
palate.  
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GI effects  
           Profuse diarrhea for 2 to 5 days after ingestion of organophosphorous 
insecticides has been reported.  
Temperature Regulation  
After exposure to most organophosphorous compounds, a marked 
hypothermia response lasting upto 24 hours has been demonstrated.
48  
Effects on Cardiovascular system 
The mechanism by which organophosphates induce cardiotoxicity is still 
uncertain. Ludomirsky et al
79
described three phases of cardiac toxicity after OP 
poisoning: 
Phase 1            Brief period of increased sympathetic tone 
Phase 2            Prolonged period of parasympathetic activity 
Phase 3            QTc prolongation followed by torsades de pointes ventricular                      
tachycardia and then ventricular fibrillation.  
Both these autonomic overactivities have been shown to cause myocardial 
damage.
80, 81
Possible other mechanisms include hypoxemia, acidosis, electrolyte 
derangements and a direct toxic effect of the compounds on the myocardium. 
36 
 
Some investigators
79, 82
described a polymorphic ventricular tachycardia of  
the torsades de pointes attributed to prolonged QTc interval. High dose atropine 
has also been implicated to cause ventricular arrhythmias.
 83, 84
 But 
Ludomirsky
79
and Lyzhnikov
80
et al both found no correlation between atropine 
therapy and VT in OP poisoning. 
Hypertension and sinus tachycardia are nicotinic while hypotension and 
sinus bradycardia are cholinergic manifestations.
 85 
Though bradycardia dominate 
the early cholinergic phase, sinus tachycardia was a more frequent finding in many 
studies.
 86, 87, 88
Some consider hypertension and tachycardia to be indicators of 
severe poisoning.
 9
  
Cardiac complications of  OP poisoning are not fully appreciated by many 
physicians. Mostly they occur during few early hours of poisoning for which the 
patient should be transferred immediately to ICU or CCU where proper 
resuscitative facilities are available. Intensive supportive treatment, meticulous 
respiratory care, and administration of  atropine in adequate doses very early are 
the keys to manage cardiac toxicity of OP compounds. 
The management of ventricular arrhythmias in OP poisoning is difficult and 
therapy has included, electrical cardioversion, lidocaine, bretylium and overdrive 
37 
 
pacing(for tachycardias),
12 
and intravenous isoproterenol, magnesium and pacing 
(for brady-cardias).
17,20,21 
 In one report of severely intoxicated patients, complete 
replacement of blood (to provide acetylcholinesterase) resulted in the 
disappearance of arrhythmias and normalisation of the QTc. 
QT prolongation 
          QT interval is a measure of the time between the start of the Q wave and 
the end of the T wave in the heart's electrical cycle. In general, the QT interval 
represents electrical depolarization and repolarization of the left and right 
ventricles. A prolonged QT interval is a biomarker for ventricular 
tachyarrhythmias like torsades de pointes and a risk factor for sudden death. 
The QT interval is dependent on the heart rate in an obvious way (the faster 
the heart rate the shorter the QT interval) and may be adjusted to improve the 
detection of patients at increased risk of ventricular arrhythmia. A quick but rough 
assessment to find QT prolongation is that, if QT is more than half of the R-R 
interval, it is supposed to be prolonged. The standard clinical correction is to use 
Bazett's formula,
89
named after physiologist Henry Cuthbert Bazett, calculating the 
heart rate-corrected QT interval QTc. 
Bazett's formula is as follows: 
QTcB=QT⁄√RR 
38 
 
where QTc is the QT interval corrected for heart rate, and RR is the interval 
from the onset of one QRS complex to the onset of the next QRS complex, 
measured in seconds, often derived from the heart rate (HR) as 60/HR (here QT is 
measured in milliseconds). However, this nonlinear formula, obtained from data in 
only 39 young men, is not accurate, and over-corrects at high heart rates and 
under-corrects at low heart rates.
90 
  
Fridericia
91
has published an alternative correction using the cube-root of RR. 
QTcF=QT⁄3√RR 
There are several other methods as well. For example a regression-based approach 
that had been developed by 
Sagie et al
92
, as follows: 
QTcL= QT + 0.154(1000-RR) 
Normal QT duration is 0.35 to 0.43
93
 adjusted to a heart rate of 60/min.  
Prolongation of the QT interval can be categorized into primary and secondary 
forms. 
 Primary(Congenital) QT prolongation includes underlying gene mutations that 
result in ion channel malfunction and congenital long QT syndromes.
 94 
Based on 
39 
 
the malfunction, the long QT syndromes (LQT) can be due to overabundance of 
sodium inflow or inadequate potassium outflow, resulting in excessive positive 
intracellular ions and delayed ventricular repolarization, like 
Jervell-Lange-Neilson syndrome (JLN1-2) - deafness, syncope and sudden death 
Romana Ward syndrome (LQT 1-6)   - no deafness  
Anderson syndrome (LQT 7)     - skeletol abnormalities like short  
                                                      stature, scoliosis etc. 
Timothy syndrome (LQT 8)      - congenital heart disease,  
                                                     musculoskeletol disease, immune dysfunction 
Secondary (acquired) QT prolongation
95, 96 
can be attributed to 
          Altered nutrition (anorexia nervosa, starvation diets, alcoholism) 
          Bradycardia (< 50 beats/min) 
          Cerebrovascular disease (intracranial and subarachnoid hemorrhage, stroke,          
intracranial trauma) 
          Diabetes mellitus 
          Elderly age 
          Electrolyte disturbances (hypokalemia, hypomagnesemia, hypocalcemia) 
          Deep sleep 
          Heart failure (cardiomyopathy, dilated or hypertrophic) 
          Hypertension 
40 
 
          Hypoglycemia 
          Hypothermia 
          Hypothyroidism 
          Myocardial ischemia or infarction
97, 98, 99 
 
          Obesity 
          Poisoning (arsenic, organophosphates, nerve gas) 
          Pituitary insufficiency 
          Drugs – A huge drug list including Amiodarone, Chloroquine, Cisapride, 
Clarithromycin, Domperidone, Erythromycin, Terfinidine, Pimozide, Quinidine, 
Sotalol etc. 
ST elevation 
An ST elevation is considered significant if the vertical distance between the 
ECG trace and the isoelectric line at a point 0.04 seconds after the J-point is at least 
1 mm in a limb lead or 2 mm in a precordial lead. This measure has a false positive 
rate of 15-20% (which is slightly higher in women than men) and a false negative 
rate of 20-30%.
100
  
Causes for ST elevation goes by the mneumonic "ELEVATION" 
E lectrolytes 
L BBB 
41 
 
E arly Repolarization 
V entricular hypertrophy 
A neurysm 
T reatment (e.g. pericardiocentesis) 
 I njury (AMI, OP poisoning, contusion) 
O sborne waves (hypothermia) 
N on-occlusive vasospasm (Prinzmetal angina) 
Low Voltage Complexes 
Diagnostic Criteria (Either of the below criteria may be met)
 100
 
                 Voltage of entire QRS complex in all limb leads <5mm. 
                 Voltage of entire QRS complex in all precordial leads < 10mm. 
Differential Diagnosis 
               An increase in the distance between the heart and the ECG leads, 
infiltration of the heart muscle itself and metabolic abnormalities are all 
associated with low voltage. 
1. Increased Distance 
                 Pericardial effusion 
                Obesity 
                COPD with hyperinflation 
                Pleural effusion 
42 
 
                Constrictive pericarditis 
2. Infiltrative Heart Disease 
                Amyloidosis 
                Scleroderma 
                Hemachromatosis 
3. Metabolic Abnormality 
                Myxoedema 
Inverted T Waves
100 
 
         Normal finding in children 
         Persistent juvenile T wave pattern 
         Myocardial ischaemia and infarction 
         Bundle branch block 
         Ventricular hypertrophy (‘strain’ patterns) 
         Pulmonary embolism 
        Hypertrophic cardiomyopathy 
        Raised intracranial pressure 
T wave inversion in lead III is a normal variant. New T-wave inversion (compared 
with prior ECGs) is always abnormal. 
Pathological T wave inversion is usually symmetrical and deep (>3mm). 
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STUDIES ON ELECTROCARDIOGRAPHIC CHANGES  IN OP 
POISONING 
• Dalvi CP, Abraham PP, Iyer SS et al stated that Abnormal ST-T wave 
changes and progressive fall in voltage or low voltage were the commonest 
ECG changes encountered. Other ECG abnormalities, like prolongation of 
QT interval, Ectopic Beats, conduction defects and peaked P waves were 
seen less frequently.  The dose of atropine required was highest and the rate 
of normalization of ECG and clinical recovery slowest, in the group with 
severe poisoning.  The mortality was higher in moderate and severe groups, 
death was sudden and clinically unexpected in patient who were appearing 
to be recovering normally clinically. Abnormal ECG changes were present 
in 40% of mild cases, 87% of moderate cases, 100% of severe 
organophosphate poisoning cases .Patient with ECG changes should be 
monitored carefully till these changes revert back to normal because even 
after transient apparent clinical recovery, these patients are prone for sudden 
death101. 
• A M Saadeh, N A Farsakh, M K Al-Ali et al studied the frequency, extent 
and pathogenesis of cardiac complications accompanying organophosphate 
and carbamate poisoning. They concluded that cardiac complications often 
accompany poisoning with these compounds particularly during first few 
44 
 
hours. 46 cases records (24 females and 22 males) were reviewed. ECG 
manifestations were, prolonged QTc interval (67%), Elevated ST segment 
(24%), inverted T waves (17%) Prolonged PR interval (9%), Atrial 
fibrillation (9%), Ventricular tachycardia (9%), Extrasystoles (6%), 
Venticular fibrillation (4%).  Other cardiac manifestations were 
noncardiogenic pulmonary oedema (43%), sinus tachycardia (35%), Sinus 
Bradycardia (28%), Hypertension (22%) and hypotension (17%). 
Hypoxemia, Acidosis and electrolyte derangements are major predisposing 
factors86.  
• S.B Agarwal, V.K Bhatnagar, Amol Agarwal, Usha Agarwal ,K.Venkaiah, 
S.K Nigam , S.K Kashyap et al studied complete clinical profile of 
organophosphate compound poisoning. In their study, sinus tachycardia, ST 
Segment depression and T wave Inversion followed by sinus bradycardia 
were the most common ECG abnormalities102. 
• P. Karki, J.A Ansari, S.Bhandary, S Koirala studied extent, frequency and 
pathogenesis of cardiac and electrocardiographic manifestation of acute 
organophosphate poisoning. They also studied clinical profile of 
organophosphate poisoning in terms of age, sex, intention, symptoms and 
signs, time interval between compound consumption and hospitalization, 
total dose of atropine given, duration of treatment with atropine, cardiac and 
45 
 
electrocardiographic manifestations. Cardiac manifestations and 
electrocardiographic changes were recorded before administration of any 
medications  ECG manifestations in their study were prolonged QTc interval 
(37.8%), ST/T changes i.e. , Elevated ST segment (16.2%), inverted T 
waves (13.5%), Prolonged PR Interval (5.4%) Atrial fibrillation (5.4%), 
Ventricular tachycardia (10.8%), Extrasystole (5.4%).  Other cardiac 
manifestations were sinus tachycardia (40.5%), Sinus bradycardia (18.9%), 
non cardiogenic pulmonary edema (21.6%), hypertension (13.5%), 
hypotension (10.8%). In this study cardiac complications developed in 
62.2% of patients, most common being Sinus tachycardia (40.5%) and 
Prolonged QTc interval (37.8%)103. 
• Ismail Hamdi kara, Cahfer Guloglu, Aziz Karabulut, Murat Orak et al 
studied sociodemographic, clinical and laboratory features of cases of 
organophosphorus intoxication and found mean age of cases 24+/-11years, 
M/F ratio 1/3.8, mostly from low socioeconomical class and of suicidal 
intention, most common ECG changes were sinus tachycardia in 58.3%, ST 
changes in 54.2 % and T changes in 12.5%. Hypokalemia followed by 
hyponatremia were the most common Electrolyte Derangements seen in 
their study104. 
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• Kumiko Taira,Yoshiko Aoyama and Miwako Kawamata studied relationship 
between ECG manifestations and subjective symptoms accompanying  
organophosphate pesticide exposure caused by aerial spray was 
investigated105.  
• Yurumez Y, Yavuz Y, Saglam H, Durukan P, Ozkan S, Akdur O, Yucel M  
evaluated 85 patients who presented to emergency department with 
Organophosphate poisoning and found QTc prolongation(55.5%) followed 
by sinus tachycardia (31.8%) were the most common Electrocardiographic 
changes106. 
• Another Indian Study by Manojith Mookherjee2 from West Bengal (1999), 
conducted a retrospective analysis of 379 patients who were admitted over 8 
years period with diagnosis of organophosphate compound poisoning. 
Cardiac complications developed in 197 (52%). These were: cardiac 
arrhythmia in 52%, prolonged QTc 46%, ST-T changes in 49% conduction 
defects in 5%, premature ventricular contractions in 67%, ventricular 
tachycardia in 2.1%, ventricular fibrillation in 0.52%, sinus tachycardia in 
40%, bradycardia in 82%, hypotension in  15% and cardiac failure in 14% of 
patients. 
• SC Chatterjee observed QTc prolongation(63.5%) followed by sinus 
tachycardia (37.5%) were the most common Electrocardiographic changes107 
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• In 1999 Mathur et al3, from Jawaharlal Nehru Hospital, Ajmer reported ECG 
changes in 120 patients with organophosphate poisoning. Sinus tachycardia 
was the most common abnormality (99.33%) followed by ST-T changes 
(91.66%), QTc prolongation (35%) and conduction blocks (8.88%). 
• Another study from Taiwan by Chuang et al5 (1996), in 223 cases of 
organophosphate compound poisoning over 12 years reported the 
electrocardiographic changes which included, Q-Tc prolongation in 43.5% 
patients. These patients had higher mortality (19.6%) and higher incidence 
of respiratory failure. Q-Tc prolongation also correlated with severity of 
poisoning. 
• Kiss and Fazekas
44 
reported QT prolongation along with ST-segment, T-
wave anomalies and other forms of arrhythmias. Recurrent ventricular 
tachycardia with the torsade de pointis phenomenon was seen. Complete 
atrioventricular block may occur.
45 
QTc prolongation indicates a poor 
prognosis and a higher incidence of respiratory failure.
46 
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3.AIM OF THE STUDY 
 
 To study the Electrocardiographic changes associated with acute 
organophosphorous poisoning. 
 To correlate these Electrocardiographic changes with the in-hospital 
course and prognosis of those patients.  
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4.METHODOLOGY 
Subjects:     Patients presenting with Organophosphorus poisoning were the study 
subjects. 
Study Design: A prospective cross-sectional study. 
Ethical committee approval:  The Ethical committee approval was obtained to 
carry out the study in the hospital a copy of which is enclosed herewith. 
Study place: Government Rajaji hospital, Madurai 
Study Duration:  April 2011 – September 2011 
Study criteria 
Inclusion Criteria: 
All adult males and females with a history of exposure to organophosphorus 
compound within previous 24 hours with characteristic clinical manifestations of 
organophosphorus compound poisoning during the study period were included. 
Exclusion Criteria: 
1) Patients who received treatment with atropine before admission 
2) Patients with doubtful diagnosis 
3) Mixed poisoning with other substances 
4) Known case of cardiac illness 
50 
 
5) Known case of long QT syndromes 
6) Patients known to be taking drugs recently which are likely to prolong QT 
interval 
Study protocol: A previously designed proforma was used to collect the 
demograpthic and clinical details of the patients. 
Collaborating department: 
           Department of Cardiology, Government Rajaji Hospital, Madurai  
Exposure Assessment 
Demography 
Age 
Sex 
Type of exposure 
Agents used 
Time interval from consumption to the time of admission 
Mode of consumption 
Poison particulars 
             Severity grading  
             Symptoms after consumption 
             Immediate steps taken after OP exposure 
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Clinical findings 
             Pupil size, mental status, secretions, fasciculations, convulsions, 
respiratory adequacy 
Data collection 
An  ECG was recorded in each case as soon as possible (usually within 15 
minutes) after admission. Treatment was not withheld in any case for the purpose 
of study. 
Serial ECGs were obtained at 12 hour intervals (or earlier if any arrhythmia 
was detected clinically) during the period of stay in the hospital. 
ECG analysis included the rate, rhythm, ST-T abnormalities, conduction 
defects and measurement of PR and QT intervals. The QT interval was corrected 
(QTc) according to the formula of Bazett 
                    QTc=QT⁄√RR 
where QTc is the QT interval corrected for heart rate, and RR is the interval 
from the onset of one QRS complex to the onset of the next QRS complex, 
measured in seconds. The period of occurrence of such ECG changes were noted 
and the time of their normalization or death of patient whichever earlier were 
noted. The final outcome were registered as death or survival. 
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Those patients requiring ventilation due to respiratory failure or IMS and 
having prolonged hospital stay, and also patients dying during stay were excluded 
in the calculation of significance of ECG events with regard to inpatient stay.  
About 112 patients fulfilling eligibility criteria were studied. Nearly 14 patients 
were excluded since they missed periodic ECG followup or brought dead before 
recording a single ECG. 
Statistical Tools  
The information collected regarding all the selected cases were recorded in a 
Master Chart. Data analysis was done with the help of computer using 
Epidemiological Information Package (EPI 2010) developed by Centre for 
Disease Control, Atlanta.  
Using this software range, frequencies, percentages, means, standard 
deviations, chi square and  'p'  values were calculated. Kruskul Wallis chi-square  
test was used to test the significance of difference between quantitative variables 
and Yate’s chi square test for qualitative variables. A 'p' value less than 0.05 is 
taken to denote significant relationship.
76,77 
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5.OBSERVATION AND RESULTS 
Figure 1-Age distribution with OP poisoning 
 
Figure 2-Sex distribution with OP poisoning
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Figure 3-Mode of consumption 
 
 
Table 3-Mode of consumption 
Poison + 
Alcohol 
Poison + 
Water 
Poison 
alone 
Poison + 
Milk 
Others 
23 13 8 3 2 
 
Thus most patients used alcohol (23%) than water (13%) and others as vehicle 
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Figure 4-OP Agents consumed 
 
 
Table 4-OP agents consumed 
Agents DM MP BK CP MC FN QP DC 
No of 
patients 
28 24 23 11 7 9 5 5 
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10% 
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Figure 5-Time Interval from intake to admission and severity 
 
Table 5-Time Interval from intake to admission and severity 
 Mild Moderate Severe 
<6 hrs 46 24 5 
6-12 hrs 2 18 5 
>12 hrs 1 4 7 
 
Thus the severity of poisoning correlates with late presentation to the hospital 
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Figure 6-Grading of secretions 
 
 
Figure 7- Exposure of poisoning 
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Figure 8-Clinical manifestations 
 
Table 6-Clinical manifestations 
Clinical features No of patients Percentage of patients 
Pin point pupils 19 16.9 
Depressed mentation 27 24.1 
Increased secretions 89 79.5 
Fasciculations 63 56.25 
Convulsions 4 3.57 
Respiratory failure 10 8.93 
IMS 4 3.57 
Tachycardia 47 41.96 
Bradycardia 24 21.43 
Hypotension 19 16.96 
Hypertension 24 21.43 
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Figure 9-Outcome 
 
 
Figure 10 –Survival and death according to severity grading 
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Figure 11-Patients categorized according to ECG changes and with severity grading 
 
Table 7-Association of ECG changes with OP poisoning regarding their number of days of 
occurrence in serial 12 hour recordings 
 
MILD MODERATE SEVERE 
P Value Significance 
 
Mean 
(days) 
SD 
Mean 
(days) 
SD 
Mean 
(days) 
SD 
QTc 2.39 0.92 1.88 0.77 1.28 0.95 0.001 Highly significant 
ST elevation 1.22 0.26 0.82 0.32 0.50 0.00 0.008 Highly significant 
T inversion 2.22 0.67 1.81 0.53 0.75 0.35 0.019 Significant 
Low voltage - - 1.75 0.35 1.41 0.99 0.651 Not significant 
PR prolongation 2.00 0.00 2.50 0.71 - - 0.424 Not significant 
AF - - 2.25 1.06 - - - Not significant 
Extra systole 0.87 0.25 1.60 0.55 0.81 0.27 0.016 Significant 
 
This observation states that the association of QTc prolongation and ST elevation 
with OP poisoning with regard to the number of days of their occurrence in serial 
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12 hour ECGs appears to be highly significant; for T inversion and Extrasystole 
appears significant; and for Low voltage complexes, PR prolongation and AF 
appears not significant.  
Figure 12-Survivors categorized according to ECG changes and with severity grading 
 
 
 
The following table states that the association of QTc prolongation, T 
inversion and Extrasystole with OP poisoning with regard to the number of days of 
their hospital stay appears to be highly significant; for Low voltage complexes 
appears significant; and for ST elevation, PR prolongation and AF appears not 
significant.  
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Table 8-Association of ECG changes with Survivors regarding their number of days of 
hospital stay 
 
MILD MODERATE SEVERE 
P Value Significance 
 
Mean 
(days) 
SD 
Mean 
(days) 
SD 
Mean 
(days) 
SD 
QTc 4.92 0.76 5.33 0.53 6.33 0.58 0.002 Highly significant 
ST elevation 4.17 0.97 4.50 0.50 - - 0.338 Not significant 
T inversion 3.75 0.27 5.08 0.73 - - <0.001 Highly significant 
Low voltage - - 5.00 0.00 6.66 0.58 0.031 Significant 
PR prolongation 4.00 0.00 5.00 1.41 - - 0.422 Not significant 
AF - - 4.00 0.00 - - - Not significant 
Extra systole 4.125 0.63 4.62 0.48 6.33 0.58 0.002 Highly significant 
 
Figure 13-Deceased patients categorized according to ECG changes and with severity 
grading 
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Table 9-Association of ECG changes with dead patients regarding their number of days of 
hospital stay 
 
MILD MODERATE SEVERE 
P Value Significance 
 
Mean 
(days) 
SD 
Mean 
(days) 
SD 
Mean 
(days) 
SD 
QTc 3.83 0.76 1.75 0.50 1.14 0.45 <0.001 Highly significant 
ST elevation - - 1.33 0.58 1.50 1.14 0.823 Not significant 
T inversion - - 4.00 4.24 0.75 0.35 0.393 Not significant 
Low voltage - - 1.50 0.41 0.875 0.44 0.039 Significant 
PR prolongation - - - - - - - Not significant 
AF - - - - - - - Not significant 
Extra systole - - 7.00 0.00 0.75 0.35 0.04 Significant 
VT 3.50 0.75 2.00 0.00 1.00 0.32 <0.001 Highly significant 
 
 
This observation states that the association of QTc prolongation and 
Ventricular tachycardia with deceased OP poisoning patients with regard to the 
number of days of their hospital stay appears to be highly significant; for Low 
voltage complexes and Extrasystole appears significant; and for ST elevation, T 
inversion,  PR prolongation and AF appears not significant.  
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Figure 14-Mean dose of atropine and P2AM with severity grading 
 
 
Table 10-Mean dose of atropine and P2AM with severity grading 
Severity grading 
Atropine treatment P2AM treatment 
Mean total dose 
(mg) 
Mean days 
Mean dose 
(g/day) 
Mean days 
Mild 46.82 ± 4.78 4.67±0.24        3.32 ±0.13 4.58±0.19 
Moderate 80.56 ± 2.76 5.39 ± 0.37        4.23 ± 0.13 5.24 ± 0.44 
Severe 138.41 ± 22.14 6.03 ± 0.54 5.76 ± 0.23 4.70 ± 0.42 
Total 88.59 ± 8.45 5.33 ± 0.43 4.43 ± 0.18 4.84 ± 0.34 
 
Atropine and Pralidoxime are the key treatment for OP poisoning. It is evident that 
the mean atropine and P2AM dose and the duration of treatment increase with 
increase in severity. 
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6.INTERESTING ECGS OBSERVED DURING THE STUDY 
 
ECG of a severe grade poison case with low voltage complexes 
 
 
A case of QT prolongation with giant T inversion who died on the 5th day 
 
A case developing torsades de pointes following QT prolongation who survived 
with defibrillation 
 
Another moderate severity case with QT prolongation who has died on the 4th day 
 
66 
 
7.DISCUSSION 
              Organophosphates and carbamates are frequently used pesticides which 
can lead to life threatening intoxication. Well over 50,000 organophosphate 
compounds have been synthesized since the first one by Clermont in 1857. All 
these compounds act by irreversible inhibition of acetylcholinesterase (Ach). The 
clinical symptoms range from classical cholinergic syndrome to flaccid paralysis 
and intractable seizures. About 99% of fatal poisoning occurs in developing 
countries particularly among farm workers. Despite an increased incidence of 
organophosphorus poisoning, the exact micromolecular changes that take place 
remain elusive. Till date atropine and oxime therapy continue to occupy the prime 
position in the specific management of OP poisoning. 
              Acute Organophosphorous compound poisoning is one of the most 
frequent poisonings encountered in Government Rajaji Hospital, Madurai. With 
the ease of availability and uncontrolled marketing, suicide has become the 
commonest mode of  poisoning in developing countries.
7, 11 
. The major cause of 
poisoning in our present study was attempted suicides (96.43%). In contrast, 
figures from developed countries like Japan, show accidental exposure forms a 
major bulk of organophosphorous compound poisoning cases.
9, 17 
This rate was 
also consistent with the findings of Mahadi Balali Mood
114 
et al about 94.3% 
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whereas it was reported to be 67% by AM Saadeh et al
86
. The accidental exposure 
in our study is only about 3.57%. 
Age, Gender Prevalence 
            The vast majority of poisonings follow oral ingestion of liquid form and for 
almost all the patients gastric lavage was immediately done. In our study, the 
incidence was higher (32.14%) in the age group of  21-30 followed by 30.35% in 
the age group of 31-40. These are consistent with the findings of Muhammet 
Guven et al
115
, S Singh et al
68 
and AM Saadeh et al
86
 where the mean values were 
24.1, 23.25 and 23.95 respectively. 
 In the present study, 79% of the patients were males. This correlates with 
the findings of the previous studies. However, in a study done by M. Vishwanathan 
et al
69
, 66% of the patients who consumed organophosphorous compound were 
females.  
Dimethoate (Rogar) accounted for about  25% of intoxication followed by 
methyl parathion and bug killer liquid of 21% each respectively. The commonest 
mode of intake was found to be poison along with alcohol about 47% followed by 
poison with water about 27%. Of  the 49 mild cases, 46 fell under early admission 
within 6 hours of intake whereas of the 12 severe cases about 7 fell under late 
68 
 
presentation of more than 12 hours establishing a direct correlation of severity with 
time delay. 
Both the present study and that of Mahdi Balali-Mood et al, found 
association between the severity of poisoning and clinical manifestations. The most 
marked muscarinic signs in our study group were, increased secretions (79.5%), 
pin point pupils (16.9%) and respiratory failure (8.93%). In studies done by OP 
Gupta et al
70
, Sarjit Singh et al
71
, and, Goel et al
64
 vomiting was present in 90% 
and 97.08% of the cases respectively due to chemical gastritis. The most prominent 
of the nicotinic effect of our study is muscular end plate block, resulting in muscle 
weakness and fasciculations (56.25%), tachycardia (41.96%), bradycardia 
(21.43%), hypotension (16.96%), hypertension (21.43%). The CNS symptoms like 
depressed mentation (24.1%) and convulsions (3.57%) were also present. In 
comparison,  studies done by Goel et al
64 
and Sarjit Singh et al
71 
showed that 55% 
and 100% of the patients respectively had fasciculations. In a study done by Robert 
et al
72 
19% of the patients had bradycardia, while in a study carried out by Semir 
Nouria
73
, 17% had bradycardia.  
About 14 (77.77%) of 18 and 16 (64%) of 25 patients of ventilator support 
and ICU care respectively belong to the severe grade of poisoning establishing 
their direct association with each other. The mean atropine and P2AM dose and the 
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duration of treatment increase with increase in severity of poisoning as observed 
with most of the reference studies. 
The outcome of study was that  20.53% of patients (23 of 112) died and 
79.46% survived (89 of 112). Though 76.46% patients survived, about 65.16% of 
survivors fell under mild grading whereas though total deaths was only 20.53%, 
about 56.52% of deceased  fell under severe grading. 
           Among the ECG changes observed overall, QTc prolongation tops the list 
with 68 cases(60.7%) followed by ST elevation (21.4%), T inversion(16.9%), 
Extra systole(12.5%), Low voltage complexes(11.6%), PR prolongation(3.5%) and 
AF(1.7%) with 24,19,14,13,4 and 2 cases respectively. This is similar to that 
observed by A M Saadeh et al, P. Karki et al, Yurumez et al, Chuang et al, Kiss 
and Fazekas
44
  and Manojith Mookherjee. The association of QTc prolongation and 
ST elevation with OP poisoning with regard to the number of days of their 
occurrence in serial 12 hour ECGs appears to be highly significant; for T inversion 
and Extrasystole appears significant; and for Low voltage complexes, PR 
prolongation and AF appears not significant. 
Among the ECG changes of survivors,  QTc prolongation tops the list with 
48 cases followed by ST elevation, T inversion, Extra systole, Low voltage 
complexes, PR prolongation and AF with 20,14,11,5,4 and 2 cases respectively. 
70 
 
Thus the association of QTc prolongation ,T inversion and Extrasystole with OP 
poisoning with regard to the number of days of their hospital stay appears to be 
highly significant; for Low voltage complexes appears significant; and for ST 
elevation, PR prolongation and AF appears not significant. This is consistent with 
that of  Rousseau JM.
66 
  
Among the patients who died, QTc prolongation tops the list with 18 cases 
followed by Low voltage complexes, Ventricular tachycardia, ST elevation, T 
inversion, Extra systole, , PR prolongation and AF with 8,5,4,4,3,2 and 0 cases 
respectively as observed Dalvi, Karki, Yemasheta M
67 
and A M Saadeh et al.Thus 
the association of QTc prolongation and Ventricular tachycardia with dead OP 
poisoning patients with regard to the number of days of their hospital stay appears 
to be highly significant; for Low voltage complexes and Extrasystole appears 
significant; and for ST elevation, T inversion,  PR prolongation and AF appears not 
significant.  
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8.CONCLUSION 
       In India, organophosphorus compounds cause more suicidal deaths among 
the earning and nonearning members of the society. This study was carried out 
with an aim to establish the correlation of  ECG changes with prognosis in OP 
poisoning. This was a cross sectional study that involved 112 OP poison cases that 
fit the criteria for our study. From all the observations and discussions made so far, 
we can conclude that 
1) The clinical features well reflected the severity of the poisoning. Patients 
presenting  later than 6 hours manifested more severity. 
2) The mean atropine and pralidoxime dosage needed appears to increase as the 
severity increases. 
3) More than half of the death cases fell under severe category 
4) ECG changes most commonly encountered were QTc prolongation (60.7%) 
followed by ST elevation (21.4%), T inversion(16.9%), Extra    
systole(12.5%), Low voltage complexes(11.6%), PR prolongation(3.5%) and 
AF(1.7%). 
5) By statistical values, QTc prolongation, ST elevation, T inversion and 
Extrasystole were significantly associated with OP poisoning. Among 
survivors,  QTc prolongation, T inversion, low voltage complexes and 
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Extrasystole were significantly associated with the prolonged duration of 
hospital stay. Among the death cases, QTc prolongation, Ventricular 
tachycardia, low voltage complexes and Extrasystole were significantly 
associated. 
6) Despite improvement in clinical features, ECG changes particularly QTc 
prolongation has got independent prognostic values as evidenced in some 
cases with good clinical recovery but with prolonged QTc interval suffered 
sudden cardiac death as a result of  torsades de pointes VT. 
                 Thus we conclude from this study that Electrocardiographic 
changes correlated independently with the prognosis of the OP poisoning 
cases and the identification of  them, particularly QTc prolongation and 
timely shifting of cases to ICU and CCU where adequate resuscitative 
measures, ventricular pacing facilities available can prevent such sudden 
cardiac deaths. Blood transfusion is said to have a role in severe poisoning in 
rapidly replenishing acetylcholinesterase enzyme. Intensive supportive care, 
meticulous respiratory care and administration of atropine in adequate 
dosage very early in the course of treatment are also emphasized. 
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9.LIMITATIONS OF THE STUDY 
 Routine biochemical recordings including serum electrolytes which can 
influence ECG changes were not observed. 
 Due to non availability, serum or RBC cholinesterase levels cannot be 
analyzed in grading the severity of poisoning. 
 Chest roentgenography findings like non-cardiogenic pulmonary edema 
were not included in severity grading. 
 Echocardiogram not included in the study. 
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PROFORMA  
 
CORRELATION OF ELECTROCARDIOGRAPHIC CHANGES WITH  
PROGNOSIS IN ORGANOPHOSPHORUS POISONING 
 
PARTICULARS OF THE PATIENT:                                                   Case No:  
Name :                                                                                           Hospital No.  
Age :  
Sex :  
Address:  
Date of Admission:  
Date of discharge:  
Suicide/accidental  
Final Diagnosis:  
 
COMPLAINTS WITH DURATION  
 - Time and date of consumption of Organophosphorous compound    
poison : 
 - Time between poisoning and admission:  
 - Compound name:                                        Trade name : 
               - Quantity consumed 
 - Mode of consumption:  
 - Inhalation / Ingestion / Injection  
 - Vomiting/ diarrhoea 
 - Altered sensorium  
 - Hyper salivation  
 - Convulsion  
 - Other Complaints  
 - Referred from :  
 
Family History:  
Past History:   
Personal History:  
 
On Examination:  
Build  
Nourishment  
Wasting  
Pallor                                                 Cyanosis                          Icterus  
Lymphadenopathy                             Clubbing                         Edema  
Pulse:                                                 Breath Smell:  
B.P:                                                    Tongue:  
R.R.:                                                   Skin:  
Temperature:  
C.N.S  
Sensorium: Normal / Restlessness / Drowsiness/Coma  
GCS:                      V E M =  
Pupils:  
Fasciculations: Total score  
Weakness  
Proximal muscle  
Neck muscle  
Respiratory muscle:  
a) Single breath count:  
b) Accessory muscle:  
P.A: 
R.S:  
C.V.S:  
 
DIAGNOSIS:  
Mild Poisoning / Moderate Poisoning / Severe Poisoning 
 
ECG interpretation (hours after admission) 
 0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5 5.0 
Rate            
Rhythm            
Low voltage            
P wave            
PR interval            
QRS width            
ST segment            
QT segment             
Corrected 
QT 
           
T wave            
Extrasystole            
VT            
 
  
Management:  
Body wash:  
Stomach wash:  
                   Dose within the first 48 hrs                Dose after 48 hrs of admission 
Atropine:  
P2AM    : 
Fluids:  
Others:  
Intubation’s Hour after the consumption of O.P. Poisoning : 
Ventilation:  
Those who developed intermediate syndrome:  
Those who developed complication                          Pneumonia  
                                                                                   Pneumothorax:  
ICU Stay (Hrs)        : 
Hospital Stay (Hrs)  : 
 
 
OUTCOME :                          RECOVERED                                EXPIRED  
 
 
P M S F C RF IMS
1 44 Male IE MP PA 3 51 130/90 - - + - - - -
2 32 Male IE BK PA 3.5 88 126/80 - + ++ + - - -
3 24 Male IE MP PW 5.5 108 112/78 - - + - - - -
4 23 Male IE DM PA 8 111 110/70 - - + - - - -
5 35 Female IE DM Ot 2.25 87 100/70 - - - - - - -
6 38 Male IE DC PA 2.25 91 150/100 - - ++ + - - -
7 27 Male IE MP PA 1.25 94 120/80 - - - - - - -
8 57 Female IE MP PW 7 118 90/60 - - ++ + - - -
9 36 Male IE QP PA 5 84 100/70 - - + - - - -
10 47 Male IE DM PA 14.25 122 80/50 + + +++ + - + -
11 22 Male IE MP PW 2.5 82 108/70 - - - - - - -
12 61 Male AE BK PA 3 58 152/98 + + +++ + + - -
13 33 Male IE FN PA 3.75 77 130/90 - - + - - - -
14 61 Male IE DM PA 8.25 132 90/60 - + ++ + - - -
15 29 Female IE MP AL 5.5 71 122/80 - - + - - - -
16 20 Male IE BK PW 8 106 116/78 - - ++ + - - -
17 19 Male IE DM PA 6 90 120/82 - - + - - + +
18 31 Male IE MP PA 7.25 102 110/70 - - ++ + - - -
19 36 Male IE CP PW 3.5 51 148/98 - - - - - - -
20 25 Female IE DC PM 3.75 112 112/70 - - ++ + - - +
21 27 Male IE DM PA 7.5 121 80/50 + + +++ + - + -
22 17 Male IE MP PA 2.5 75 120/90 - - + - - - -
23 20 Male IE BK PA 5.5 68 100/70 - + ++ + - - -
24 44 Female AE FN Ot 9 53 140/100 - - + - - - -
25 36 Male IE DM PW 3.5 73 120/80 - + ++ + - - -
26 39 Male IE MP PW 3.25 118 128/90 - - ++ + - - -
27 50 Male IE BK PA 2.5 123 90/50 + + +++ + - - -
Type of 
exposure Agents
SL. 
NO Age Sex
Mode of 
consumption
Time interval 
(consumption 
to admission) 
in hours
Pulse 
rate per 
min
BP          
(mm Hg)
MASTER CHART
Clinical features
P M S F C RF IMS
28 59 Male IE CP PA 1.75 49 150/90 - - - - - - -
29 23 Male IE DM PA 6.5 87 110/80 - + ++ + - - -
30 18 Male IE BK PM 4 81 120/88 - - + - - - -
31 29 Male IE FN PW 8 125 122/80 - + ++ + - - -
32 27 Female IE DM AL 14 79 110/70 - - ++ + - - -
33 41 Male IE BK PW 13 113 70/40 + + +++ + - + -
34 39 Male IE DM PA 3.5 55 150/90 - - + - - - -
35 34 Male IE MP PA 3 107 102/78 - - ++ + - - -
36 19 Male IE DM PA 9.5 66 100/70 - + ++ + - - -
37 27 Female IE MC AL 2.5 69 120/80 - - + - - - -
38 29 Male IE FN PW 8 109 90/60 + + ++ + - - -
39 32 Male AE DM PW 5 89 110/80 - - + - - - -
40 37 Female IE BK PM 5.5 112 122/84 - - ++ + - - -
41 47 Female IE MP PW 6.5 51 160/100 + + +++ + + - -
42 51 Male IE DM PA 4.5 57 164/90 - - ++ + - - -
43 17 Male IE QP PA 11 115 124/82 - - ++ + - - -
44 28 Male IE BK PA 2.5 91 134/82 - - + - - - -
45 33 Female IE DM AL 8 106 80/40 + + +++ + - + -
46 15 Male IE MP PW 1 76 100/70 - - + - - -
47 29 Male IE MC AL 0.75 89 110/80 - - - - - - -
48 34 Male IE BK PA 8.75 114 122/84 - - ++ + - - -
49 37 Male IE DM PA 1.5 53 130/90 - - + - - - -
50 45 Male IE MP PA 16 59 156/102 - - ++ + - - -
51 54 Female IE DC PM 4 45 160/90 - - - - - - -
52 26 Male IE BK PW 16 134 78/52 + + +++ + + - -
53 30 Female IE DM PW 5.25 75 120/84 - - ++ + - - -
54 39 Male IE MP AL 2.25 93 100/70 - - - - - - -
55 24 Female IE CP PW 4.5 87 110/80 - - - - - - -
SL. 
NO Age Sex
Type of 
exposure Agents
Clinical featuresMode of 
consumption
Time interval 
(consumption 
to admission) 
in hours
Pulse 
rate per 
min
BP          
(mm Hg)
MASTER CHART
P M S F C RF IMS
56 21 Male IE BK PA 4.5 118 104/80 - - ++ + - - -
57 52 Male IE DM PA 3.5 48 160/100 - - + - - - -
58 19 Male IE MP PA 5 133 100/78 - - ++ + - - -
59 22 Male IE BK AL 7 90 120/80 - - ++ + - - -
60 27 Male IE FN AL 7.5 104 128/82 - - ++ + - - -
61 37 Male IE DM PW 7 142 84/56 + + +++ + - + -
62 39 Female IE MP PW 2 95 110/70 - - ++ + - - -
63 63 Male IE QP AL 1.5 50 166/98 - - + - - - -
64 46 Male IE BK PA 2.5 45 152/90 - - + - - - -
65 17 Male IE MP PA 11.5 78 120/90 - - ++ + - - -
66 49 Male IE CP PA 7 ? ?? + + +++ + - + -
67 33 Female IE MC AL 4.5 82 134/90 - - - - - - -
68 15 Male IE FN PW 3 90 128/80 - - ++ + - - -
69 28 Male IE MP PA 7.5 55 110/80 - - ++ + - - -
70 32 Male IE MC PA 2 51 148/100 - - - - - - -
71 38 Male IE MP PA 3,5 141 92/58 + + +++ + - - -
72 61 Male IE DM AL 10 76 100/70 + - ++ + - - +
73 49 Female IE FN AL 4.5 48 154/98 - - + - -  - -
74 55 Male IE BK PW 3 75 150/90 - - - - - - -
75 24 Male IE DM PW 2.5 80 120/80 - - ++ + - - -
76 29 Female IE CP AL 5.5 53 150/88 + + +++ + - - -
77 30 Male IE MC PA 4 79 130/90 - - + - - - -
78 44 Male IE MP PA 4.5 148 88/52 + + +++ + - - -
79 61 Male IE DM PA 13 87 100/60 - - - - - - -
80 30 Female IE FN AL 8.25 114 110/82 - - ++ + - - -
81 39 Male IE BK PW 13 81 90/60 - - ++ + - - -
82 31 Male IE CP PW 2.5 70 120/80 - - - - - - -
83 22 Male IE MP AL 4.5 73 130/90 - - - - - - +
84 27 Female IE CP PM 4.5 112 128/82 - - ++ + - - -
Mode of 
consumption
Time interval 
(consumption 
to admission) 
in hours
Pulse 
rate per 
min
BP          
(mm Hg)
Clinical featuresSL. 
NO Age Sex
Type of 
exposure Agents
MASTER CHART
P M S F C RF IMS
85 19 Male IE DM PW 1 85 100/72 - - - - - - -
86 41 Male IE CP PA 5.5 128 94/58 - + ++ + - - -
87 58 Male IE MP PA 2.75 56 156/100 - - + - - - -
88 49 Male IE BK PA 14 ? ?? + + +++ + + + -
89 26 Female IE DM AL 1.5 121 118/88 - - ++ + - - -
90 19 Male IE QP PW 2 83 102/70 - - - - - - -
91 30 Female IE BK AL 4 90 110/70 - - ++ + - - -
92 37 Male IE DM PW 4 56 150/98 - - - - - - -
93 32 Male IE CP PA 3 65 130/90 - - - - - - -
94 50 Male IE BK PA 12.5 120 70/40 + + +++ + - - -
95 26 Male IE DC PA 4.75 74 120/80 - - + - - - -
96 29 Male IE MP PA 5 89 110/80 - - + - - - -
97 31 Male IE MC PA 7 114 112/78 - - ++ + - - -
98 37 Male IE FN AL 3.5 76 148/96 - - ++ + - - -
99 33 Female IE DM PW 15 135 70/42 + + +++ + - + -
100 40 Male IE BK PA 5.25 85 118/80 - - ++ + - - -
101 22 Male IE CP PA 2.5 69 100/74 - - + - - - -
102 49 Male IE DC PA 3.5 49 160/90 - - - - - - -
103 28 Female AE BK AL 8 114 118/70 - - ++ + - - -
104 22 Male IE DM PW 2 88 122/88 - - - - - - -
105 18 Male IE MC PM 1.75 84 100/70 - - - - - - -
106 46 Male IE BK AL 13.5 165 60/? + + +++ + - + -
107 62 Male IE DM PW 3 51 160/90 - - + - - - -
108 37 Male IE CP AL 2 121 100/72 - - ++ + - - -
109 31 Male IE MP PA 9.5 59 156/92 - - ++ + - - -
110 29 Male IE QP PA 5.5 90 110/80 - + ++ + - - -
111 23 Male IE BK PA 5.75 117 100/70 - - - - - - -
112 35 Female IE DM PW 15 51 150/90 - - ++ + - - -
Mode of 
consumption
Time interval 
(consumption 
to admission) 
in hours
Pulse 
rate per 
min
BP          
(mm Hg)
Clinical featuresSL. 
NO Age Sex
Type of 
exposure Agents
MASTER CHART
A N A N A N A N A N A N A N A N At Pr V ICU HS O
1 - - - - - - - - - - - - - - 1 3 75 3 - - 5 S
2 - - - - - - - - - - 1 3 - - - - 75 4 - - 5 S
3 - - - - 1 4.5 - - - - - - - - - - 59 3 - - 4 S
4 - - - - - - - - - - - - 4 - 2 - 50 3 - - 4 D
5 - - - - - - - - - - - - - - 0.5 4 39 3 - - 6 S
6 - - 0.5 1.5 - - - - - - - - - - - - 85 4 - - 4 S
7 - - - - - - - - - - - - - - 1 3 35 3 - - 5 S
8 - - 0.5 - - - - - - - - - - - - - 154 4 - - 1 D
9 - - - - - - - - - - - - - - 2 4 40 3 - - 6 S
10 0 - - - - - - - - - - - - - 0 - 125 5 0.5 0.5 1 D
11 - - - - - - - - - - - - - - 1.5 3 43 3 - - 5 S
12 0 2.5 - - - - - - - - - - - - - - 175 5.5 - 5 7 S
13 - - 0.5 2 - - - - - - - - - - - - 47 3 - - 3.5 S
14 - - - - - - - - - - - - - - 1.5 - 100 4 - 1 2 D
15 - - - - 0.5 4 - - - - - - - - - - 54 3 - - 3.5 S
16 - - - - - - 1 3 - - - - - - - - 75 4 - - 4 S
17 - - - - - - - - - - - - - - 1 6 59 4 11 11 18 S
18 - - - - - - - - - - - - 3 3 1 4 65 4 - 3 6 S
19 - - - - - - - - - - - - - - 1 4 46 4 - - 6 S
20 - - - - - - - - - - - - - - 1.5 3 55 4 6 6 12 S
21 0 - - - - - - - - - - - - - 0.5 - 220 5 1 1 1.5 D
22 - - - - - - - - - - - - - - 1.5 3 43 3 - - 5 S
23 - - 1 2 - - - - - - - - - - - - 85 4 - - 4 S
24 - - - - - - - - - - - - - - 1 4 43 4 - - 6 S
25 - - - - 1 3 - - - - - - - - - - 85 5.5 - - 5 S
26 - - - - - - - - - - - - - - 1 3 65 4 - - 5 S
27 0 3 - - - - - - - - 2 3 - - 0 3 100 7 3.5 3.5 6 S
SL. 
NO
Inverted T Prolonged PR Interval
Ventricular 
tachycardia
QTc 
Prolongation
Low 
Voltage ST elevation
Atrial 
fibrillation
Extra 
systole
MASTER CHART
Treatment
A N A N A N A N A N A N A N A N At Pr V ICU HS O
28 - - - - - - - - - - - - - - 2.5 4 37 4 - - 7 S
29 - - - - - - - - - - - - - - 1 2.5 78 5.5 - - 5 S
30 - - - - 1 2.5 - - - - - - - - - - 50 3 - - 4 S
31 - - - - - - - - - - - - - - 0 3 68 4 - - 5 S
32 - - - - - - - - - - 2 4 - - - - 60 4 - - 5 S
33 0 - - - - - - - - - 0 - - - 0 - 144 5.5 0.5 0 0.5 D
34 - - 0.5 1.5 - - - - - - - - - - - - 47 3 - - 4 S
35 0 2 - - - - - - - - - - - - - - 100 4 - - 5 S
36 - - 0.5 1.5 - - - - - - - - - - - - 84 5.5 - - 5 S
37 - - - - - - - - - - - - - - 1 3.5 46 3 - - 6 S
38 - - - - - - - - - - - - - - 0.5 - 135 4 - 0.5 1 D
39 - - - - - - - - - - 1 2 - - - - 37 3 - - 4 S
40 - - - - 1.5 2.5 - - - - - - - - 0.5 3 84 5.5 - - 5.5 S
41 - - - - - - - - - - - - - - 1 - 95 7 2 2 2 D
42 - - 1 1.5 - - - - - - - - - - - - 96 4 - - 4 S
43 - - - - 0 2.5 - - - - - - - - 0.5 2.5 70 4.5 - - 6 S
44 - - - 1 3 - - - - - - - - - - 55 3 - - 4 S
45 0 - - - - - - - - - - - - - 0.5 - 130 7 1 1 1.5 D
46 - - - - - - - - - - - - - - 1.5 - 45 3 - - 4.5 D
47 - - - - - - - - - - - - - - 0 4 44 4 - - 6 S
48 - - 1 1.5 - - - - - - - - - - - - 75 4.5 - - 5 S
49 - - - - - - - - - - - - - - 1 3 49 4 - - 5 S
50 - - 0 1 - - - - - - - - 2 - 1 - 100 4 - - 2 D
51 - - - - - - - - - - - - - - 0.5 3.5 47 4 - - 5 S
52 - - - - 0 - - - - - 0 - 1 - 0 - 155 7 1 1 1 D
53 - - 0.5 1 - - - - - - - - - - - - 94 5.5 - - 4 S
54 - - - - 0.5 2.5 - - - - - - - - - - 47 3 - - 3.5 S
55 - - - - - - - - - - 1.5 2 - - - - 49 3 - - 3.5 S
Low 
Voltage ST elevation
Atrial 
fibrillation
Extra 
systole
MASTER CHART
Ventricular 
tachycardia
QTc 
Prolongation TreatmentInverted T
Prolonged 
PR IntervalSL. 
NO
A N A N A N A N A N A N A N A N At Pr V ICU HS O
56 - - - - - - - - 1 4 - - - - - - 90 4 - - 4 S
57 - - 0 1 - - - - - - - - - - - - 53 3 - - 4 S
58 0 1.5 - - - - - - - - - - - - - - 110 4 - - 5 S
59 - - - - 0.5 2.5 - - - - - - - - 0.5 2.5 74 4.5 - - 4.5 S
60 - - - - - - - - - - - - - - 1 2.5 65 4 - - 5 S
61 - - - - - - - - - - - - 1 - 0 - 132 7 1 1 1 D
62 - - 1 2 - - - - - - - - - - 1 2 70 4 - - 5 S
63 - - 0 1.5 - - - - - - - - - - 2 4.5 49 4 - - 6 S
64 - - - - - - 1 3 - - - - - - - - 55 3 - - 4 S
65 - - - - - - - - - - - - - - 0 2 75 4 - - 5 S
66 0 - - - 0 - - - - - - - 0.5 - - - 205 5 0.5 0.5 0.5 D
67 - - - - 1 3.5 - - - - - - - - - - 45 3 - - 3.5 S
68 - - - - - - - - - - - - - - 0.5 2 84 4 - - 5 S
69 - - 0.5 1 - - - - - - - - - - - - 65 4 - - 4 S
70 - - - - - - - - - - - - - - 1 4 39 4 - - 6 S
71 0 3 - - - - - - - - 2.5 3 - - 0 3 85 6 - 4 7 S
72 - - - - 1 - - - - - 2 4 - - - - 120 4.5 4 4 7 D
73 - - - - - - - - - - - - - - 0 3 57 3 - - 5 S
74 - - - - 0.5 2.5 - - - - - - - - - - 46 3 - - 3.5 S
75 - - - - - - - - - - - - - - 1 3 55 4 - - 6 S
76 - - - - - - - - - - 2 3 - - 0 3 105 6 - - 6 S
77 - - - - - - - - - - 0.5 1.5 - - - - 40 4 - - 4 S
78 - - 1 1.5 - - - - - - - - 1.5 - 1 - 138 6 1 1 1.5 D
79 - - - - - - - - - - - - 2 - 2 - 49 2 - - 3 D
80 - - - - - - - - - - - - - - 0.5 2.5 85 4 - - 5 S
81 - - 0.5 - 0 - - - - - - - - - - - 85 4 - - 1 D
82 - - 0.5 1.5 - - - - - - - - - - - - 40 3 - - 3 S
83 - - - - 1 2.5 - - - - - - - - - - 69 3 19 19 24 S
84 - - 1 2 - - - - - - 1 2 - - 1 2.5 68 4.5 - - 4.5 S
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85 - - - - - - - - - - - - - - 1 3 38 4 - - 5 S
86 - - - - - - 0.5 3.5 - - - - - - - - 65 4 - - 6 S
87 - - - - - - - - - - - - - - 1.5 3 44 3 - - 5 S
88 0 - - - - - - - - - - - - - - - 125 4 0.5 0.5 0.5 D
89 - - - - - - - - - - - - - - 0 3 64 4.5 - - 6 S
90 - - - - - - - - - - - - - - 2 5 36 3 - - 7 S
91 - - - - 1 3 - - - - - - - - 1 3 65 4 - - 5.5 S
92 - - - - - - - - - - - - - - 1 4 39 4 - - 6 S
93 - - 1 2 - - - - - - - - - - - - 45 3 - - 4 S
94 - - - - - - - - - - - - 1 - 0 - 164 5 1 1 1 D
95 - - - - - - - - - - 2 3 - - - - 57 3 - - 5 S
96 - - - - - - - - - - - - - - 0.5 3 49 3 - - 5 S
97 - - - - - - - - - - - - 3 3 0.5 4.5 64 4 - 3 6 S
98 - - 0.5 1.5 - - - - - - - - - - 0.5 1.5 88 4 - - 5 S
99 0 - - - - - - - - - - - 1 - 0 - 145 5 1 1 1 D
100 - - - - - - - - - - - - - - 1 4 74 4 - - 6 S
101 - - - - - - 0.5 2.5 - - - - - - - - 53 3 - - 4 S
102 - - - - - - - - - - - - - - 2 4.5 37 4 - - 6 S
103 - - - - - - - - 0.5 1 - - - - - - 70 4.5 - - 4 S
104 - - 0 1 - - - - - - - - - - 1.5 3 40 4 - - 5 S
105 - - - - 2 4 - - - - - - - - - - 43 3 - - 4 S
106 0 - - - - - - - - - - - - - 0 - 110 5 0.5 0.5 0.5 D
107 - - 0 1.5 - - - - - - - - - - 3 5 38 3 - - 5.5 S
108 - - - - - - - - - - - - - - 0 3 74 4 - - 5 S
109 - - 1 2.5 - - - - - - - - - - 1 2.5 105 4 - - 6 S
110 - - - - 0.5 2.5 - - - - 0.5 2.5 - - - - 78 4 - - 4 S
111 - - 0.5 2 - - - - - - - - - - - - 47 3 - - 3.5 S
112 - - - - - - - - - - - - 2 - 0.5 - 90 4 - 1 2 D
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KEYS TO MASTER CHART 
 
 
TYPE OF EXPOSURE 
     IE                   -  Intentional Exposure 
    AE                  -  Accidental Exposure 
 
 
AGENTS USED 
    DM                  -  Dimethoate 
    MP                   - Methyl parathion 
    BK                   - Bug killer liquid 
    CP                   - Chlorpyrifos 
    MC                  - Monochrotophos 
    FN                   - Fenthion 
    QP                   - Quinolphos 
    DC                   - Dichlorofos 
 
 
MODE OF CONSUMPTION 
    PA                   - Poison + Alcohol 
    PW                  - Poison + Water 
    AL                   - Poison alone 
    PM                  - Poison + Milk 
    Ot                    - Other modes eg: mixing with food etc 
 
 
CLINICAL FEATURES 
     P                      - Pinpoint pupils 
    M                    - Depressed mental status 
    S                      - Secretions      +          Mild 
                                                     ++        Moderate  
                                                     +++      Severe  
    F                      -  Fasciculations 
    C                     -  Convulsions 
    RF                   -  Respiratory Failure 
    IMS                 -  Intermediate syndrome   
    BP                   -  Blood pressure 
 
 
ECG CHANGES 
    A                     -  Appearance  (days after admission) 
    N                     -  Normalization (days after admission) 
 
TREATMENT 
       At                     -  Atropine  total dosage needed 
       Pr                     -  Pralidoxime dose needed per day 
       V                     -  Ventilator support  started (days after admission) 
       ICU                 -  Intensive care unit started (days after admission) 
       HS                   -  Hospital stay duration in days 
       O                     -  Outcome        S        Survival 
                                                         D       Death 
                                          
ABBREVIATIONS 
 
ACh                         - Acetyl choline 
AChE/ChE              - Acetyl cholinesterase 
ACTH                      - Adrenocorticotropic hormone 
AF                            - Atrial Fibrillation 
ARDS                      - Adult respiratory distress syndrome 
ATP                         - Adenosine triphosphate 
CNS                         - Central Nervous System 
CCU                         - Coronary care unit 
ECG                         - Electrocardiograph 
ICU                          - Intensive care unit 
M/F                          - Male/Female 
NTE                         - Neuropathy Target Esterase 
OP                            - Organophosphorus 
PAM/P2AM            - Pralidoxime (Pyridine-2-aldoxime methyl chloride) 
RBC                         - Red blood cell 
VT                            - Ventricular Tachycardia 
WHO                       - World Health Organisation 
 
